EGFR and breast cancer: MMP-1 has been proposed as a biomarker for breast cancer [14,53]; understanding its role in activation of the TGFα/EGFR signal pathway may lead to the use or development of additional targeted agents to suppress this axis, and result in improved treatments for metastatic breast cancer.